Short-term Efficacy Observation of Different Chemotherapy Schemes Combined with Cisplatin on Cervical Cancer before Operation
JI Yi-mei
Abstract
JI Yi-mei
Abstract
OBJECTIVE:To observe the short-term efficacy and safety of cisplatin combined with different chemotherapy schemes for cervical cancer before operation.METHODS:135 inpatients with cervical cancer in our hospital from Jan.2009 to Dec.2011 were randomly divided into first treatment group(67 cases) and second treatment group(68 cases).First treatment group received irinotecan(60 mg.m-2,d 1,d 8)combined with cisplatin chemotherapy(60 mg.m-2,d 2);second treatment group was given leurocristine(1 mg.m-2,d 1),bleomycin(15 mg.m-2,d 1,d 2)and cisplatin chemotherapy(100 mg.m-2,d 1).15~20 days after chemotherapy,all patients received extensive hysterectomy and pelvic lymph node dissection.14 days after chemotherapy,short-term efficacy and adverse drug reaction were evaluated,and the tumor infiltration of local lesion and lymph node were checked during and after operation.RESULTS:There were no significant difference in CR,PR,ORR between 2 groups(P 0.05).Preoperative chemotherapy inhibited the local lesion significantly in 2 groups,and the operation obtained satisfactory effects.There was no statistical significance in tumor cell infiltration of peripheral tissues and pelvic lymphs between 2 groups(P0.05).There was no statistical significance in gastrointestinal reactions in 2 groups(P0.05).The degree of bone marrow suppression in first treatment group was lighter than in second treatment group(P0.01).CONCLUSION:Preoperative chemotherapy plays a positive role on improvement of disease situation.Both irinotecan combined with cisplatin and leurocristine+bleomycin combined with cisplatin obtain sound therapeutic efficacies.The degree of bone marrow suppression of the latter is more serious,but it can be improved by symptomatic treatment.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE:To observe the short-term efficacy and safety of cisplatin combined with different chemotherapy schemes for cervical cancer before operation.METHODS:135 inpatients with cervical cancer in our hospital from Jan.2009 to Dec.2011 were randomly divided into first treatment group(67 cases) and second treatment group(68 cases).First treatment group received irinotecan(60 mg.m-2,d 1,d 8)combined with cisplatin chemotherapy(60 mg.m-2,d 2);second treatment group was given leurocristine(1 mg.m-2,d 1),bleomycin(15 mg.m-2,d 1,d 2)and cisplatin chemotherapy(100 mg.m-2,d 1).15~20 days after chemotherapy,all patients received extensive hysterectomy and pelvic lymph node dissection.14 days after chemotherapy,short-term efficacy and adverse drug reaction were evaluated,and the tumor infiltration of local lesion and lymph node were checked during and after operation.RESULTS:There were no significant difference in CR,PR,ORR between 2 groups(P 0.05).Preoperative chemotherapy inhibited the local lesion significantly in 2 groups,and the operation obtained satisfactory effects.There was no statistical significance in tumor cell infiltration of peripheral tissues and pelvic lymphs between 2 groups(P0.05).There was no statistical significance in gastrointestinal reactions in 2 groups(P0.05).The degree of bone marrow suppression in first treatment group was lighter than in second treatment group(P0.01).CONCLUSION:Preoperative chemotherapy plays a positive role on improvement of disease situation.Both irinotecan combined with cisplatin and leurocristine+bleomycin combined with cisplatin obtain sound therapeutic efficacies.The degree of bone marrow suppression of the latter is more serious,but it can be improved by symptomatic treatment.
Key concepts: Cisplatin, Medicine, Irinotecan, Chemotherapy, Cervical cancer, Bleomycin, Bone marrow suppression, Lymph node